129 related articles for article (PubMed ID: 15527103)
1. Dexamethasone mediated inhibition of local IL-2 immunotherapy is dose dependent in experimental brain tumors.
Lesniak MS; Gabikian P; Tyler BM; Pardoll DM; Brem H
J Neurooncol; 2004 Oct; 70(1):23-8. PubMed ID: 15527103
[TBL] [Abstract][Full Text] [Related]
2. Gene therapy for experimental brain tumors using a xenogenic cell line engineered to secrete hIL-2.
Lesniak MS; Tyler BM; Pardoll DM; Brem H
J Neurooncol; 2003; 64(1-2):155-60. PubMed ID: 12952296
[TBL] [Abstract][Full Text] [Related]
3. Comparative analysis of paracrine immunotherapy in experimental brain tumors.
Lesniak MS; Sampath P; DiMeco F; Viglione MP; Tyler BM; Pardoll DM; Brem H
Neurosurg Focus; 2000 Dec; 9(6):e4. PubMed ID: 16817687
[TBL] [Abstract][Full Text] [Related]
4. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
5. Intracranial paracrine interleukin-2 therapy stimulates prolonged antitumor immunity that extends outside the central nervous system.
Ewend MG; Thompson RC; Anderson R; Sills AK; Staveley-O'Carroll K; Tyler BM; Hanes J; Brat D; Thomas M; Jaffee EM; Pardoll DM; Brem H
J Immunother; 2000; 23(4):438-48. PubMed ID: 10916753
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system.
Sampson JH; Archer GE; Ashley DM; Fuchs HE; Hale LP; Dranoff G; Bigner DD
Proc Natl Acad Sci U S A; 1996 Sep; 93(19):10399-404. PubMed ID: 8816812
[TBL] [Abstract][Full Text] [Related]
7. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
Sampath P; Hanes J; DiMeco F; Tyler BM; Brat D; Pardoll DM; Brem H
Cancer Res; 1999 May; 59(9):2107-14. PubMed ID: 10232596
[TBL] [Abstract][Full Text] [Related]
8. Cross-priming of T cells to intracranial tumor antigens elicits an immune response that fails in the effector phase but can be augmented with local immunotherapy.
Velicu S; Han Y; Ulasov I; Brown IE; El Andaloussi A; Gajewski TF; Lesniak MS
J Neuroimmunol; 2006 May; 174(1-2):74-81. PubMed ID: 16504307
[TBL] [Abstract][Full Text] [Related]
9. Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells.
Hinrichs CS; Palmer DC; Rosenberg SA; Restifo NP
J Immunother; 2005; 28(6):517-24. PubMed ID: 16224268
[TBL] [Abstract][Full Text] [Related]
10. Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.
Kjaergaard J; Peng L; Cohen PA; Drazba JA; Weinberg AD; Shu S
J Immunol; 2001 Dec; 167(11):6669-77. PubMed ID: 11714839
[TBL] [Abstract][Full Text] [Related]
11. Intratumoral interleukin-2/agonist CD40 antibody drives CD4+ -independent resolution of treated-tumors and CD4+ -dependent systemic and memory responses.
Jackaman C; Nelson DJ
Cancer Immunol Immunother; 2012 Apr; 61(4):549-60. PubMed ID: 22002241
[TBL] [Abstract][Full Text] [Related]
12. Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model.
Foureau DM; McKillop IH; Jones CP; Amin A; White RL; Salo JC
Cancer Immunol Immunother; 2011 Sep; 60(9):1347-56. PubMed ID: 21638127
[TBL] [Abstract][Full Text] [Related]
13. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy.
Stagg J; Lejeune L; Paquin A; Galipeau J
Hum Gene Ther; 2004 Jun; 15(6):597-608. PubMed ID: 15212718
[TBL] [Abstract][Full Text] [Related]
14. Induction of antigen-specific immune responses against malignant brain tumors by intramuscular injection of sindbis DNA encoding gp100 and IL-18.
Yamanaka R; Xanthopoulos KG
DNA Cell Biol; 2005 May; 24(5):317-24. PubMed ID: 15869409
[TBL] [Abstract][Full Text] [Related]
15. IL-12 gene therapy using an electrically mediated nonviral approach reduces metastatic growth of melanoma.
Lucas ML; Heller R
DNA Cell Biol; 2003 Dec; 22(12):755-63. PubMed ID: 14683586
[TBL] [Abstract][Full Text] [Related]
16. Modulation of specific active immunization against murine melanoma using recombinant cytokines.
Stidham KR; Ricci WM; Vervaert C; Abdel-Wahab Z; Seigler HF; Darrow TL
Surg Oncol; 1996; 5(5-6):221-9. PubMed ID: 9129134
[TBL] [Abstract][Full Text] [Related]
17. Intracerebral versus subcutaneous immunization with allogeneic fibroblasts genetically engineered to secrete interleukin-2 in the treatment of central nervous system glioma and melanoma.
Glick RP; Lichtor T; Mogharbel A; Taylor CA; Cohen EP
Neurosurgery; 1997 Oct; 41(4):898-906; discussion 906-7. PubMed ID: 9316052
[TBL] [Abstract][Full Text] [Related]
18. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
[TBL] [Abstract][Full Text] [Related]
19. Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors.
Iwadate Y; Tagawa M; Namba H; Oga M; Kawamura K; Tasaki K; Sakiyama S; Yamaura A
Cancer Gene Ther; 2000 Sep; 7(9):1263-9. PubMed ID: 11023199
[TBL] [Abstract][Full Text] [Related]
20. Combined local hyperthermia and immunotherapy treatment of an experimental subcutaneous murine melanoma.
Geehan DM; Fabian DF; Lefor AT
J Surg Oncol; 1995 May; 59(1):35-9. PubMed ID: 7745975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]